Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENSEMBLE 2: Ad26.COV2.S Two-Dose Vaccine Efficacy Study
NCT04614948Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Jun 2023
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ad26.COV2.S with Placebo (2 arms). Primary endpoint: Number of Participants With First Occurrence of Molecularly Confirmed Moderate to Severe/Critical COVID-19 in Seronegative Participants With Onset at Least 14 Days After the Second Vaccination. Started Nov 2020; status: completed.
02
Drugs
Ad26.COV2.S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04614948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04614948.